Table 1.
Baseline Characteristics of Patients Stratified by the Types of LAAO Devices
| Variables | Total (n=107) | LAmbre (n=59) | Lefort (n=25) | WATCHMAN (n=9) | Leftear (n=14) |
|---|---|---|---|---|---|
| Age (years) | 70.7±9.5 | 71.2±9.5 | 71.2±7.7 | 67.2±14.5 | 70.0±8.8 |
| Age ≥ 75 yrs (%, n) | 48.6% (52) | 23.4% (25) | 13.1% (14) | 3.7% (4) | 8.4% (9) |
| Male/Female | 54/53 | 28/31 | 12/13 | 6/3 | 8/6 |
| Persistent AF (%, n) | 72.9% (78) | 11.2% (12) | 48.6% (52) | 3.7% (4) | 9.3% (10) |
| SBP (mmHg) | 134.3±16.7 | 134.5±16.0 | 134.2±16.4 | 137.6±23.4 | 131.6±16.6 |
| DBP (mmHg) | 77.4±13.6 | 79.5±13.4 | 74.6±13.6 | 76.4±18.0 | 74.4±11.1 |
| CHF (%, n) | 26.2% (28) | 3.7% (4) | 7.5% (8) | 6.5% (7) | 8.4% (9) |
| Hypertension (%, n) | 56.1% (60) | 35.5% (38) | 14.0% (15) | 3.7% (4) | 2.8% (3) |
| Diabetes (%, n) | 30.8% (33) | 11.2% (12) | 6.5% (7) | 5.6% (6) | 7.5% (8) |
| Prior Stroke/TIA (%, n) | 50.4% (55) | 34.6% (37) | 9.3% (10) | 1.9% (2) | 4.7% (5) |
| Lipid disorders (%, n) | 29.0% (31) | 3.7% (4) | 9.3% (10) | 6.5% (7) | 9.3% (10) |
| Warfarin (%, n) | 41.1% (44) | 15.9% (17) | 8.4% (9) | 5.6% (6) | 11.2% (12) |
| Aspirin (%, n) | 19.6% (21) | 9.3% (10) | 7.5% (8) | 0.9% (1) | 1.9% (1) |
| Clopidogrel (%, n) | 15.0% (16) | 5.6% (6) | 6.5% (7) | 1.9% (2) | 0.9% (1) |
| Statins (%, n) | 15.9% (17) | 6.5% (7) | 3.7% (4) | 0 | 5.6% (6) |
| Nitrates (%, n) | 24.3% (26) | 5.6% (6) | 6.5% (7) | 5.6% (6) | 6.5% (7) |
| Amiodarone (%, n) | 40.2% (43) | 8.4% (9) | 12.1% (13) | 6.5% (7) | 13.1% (14) |
| ACEI/ARB (%, n) | 48.6% (52) | 26.2% (28) | 11.2% (12) | 5.6% (6) | 5.6% (6) |
| Beta-blocker (%, n) | 18.7% (20) | 7.5% (8) | 7.5% (8) | 2.8% (3) | 0.9% (1) |
| Diuretics (%, n) | 29.9% (32) | 7.5% (8) | 12.1% (13) | 4.7% (5) | 5.6% (6) |
| CCB (%, n) | 37.4% (40) | 15.0% (16) | 10.3% (11) | 5.6% (6) | 6.5% (7) |
| Digoxin (%, n) | 29.9% (32) | 4.7% (5) | 5.6% (6) | 7.5% (8) | 12.1% (13) |
| CHADS2 Score | 2.67±1.45 | 2.42±1.42 | 2.40±1.66 | 3.67±1.41 | 3.57±1.40 |
| CHA2DS2-VAS Score | 4.21±1.97 | 3.90±1.77 | 3.76±2.28 | 5.33±1.58 | 5.57±1.42 |
| HAS-BLED Score | 3.08±1.53 | 3.27±1.68 | 2.84±1.43 | 2.89±1.27 | 2.86±1.23 |
| NYHA (I/II/III) | 63/28/15 | 41/10/7 | 17/5/3 | 2/6/1 | 3/7/4 |
| Post-intervention antithrombotic regimen | |||||
| Post-intervention to 24h: enoxaparin (%, n) | 100.0% (107) | 100.0% (59) | 100.0% (25) | 100.0% (9) | 100.0% (14) |
| Post-intervention to 3 months: aspirin combined with clopidogrel (%, n) | 100.0% (107) | 100.0% (59) | 100.0% (25) | 100.0% (9) | 100.0% (14) |
| Three months after the intervention: aspirin or clopidogrel (%, n) | 100.0% (107) | 100.0% (59) | 100.0% (25) | 100.0% (9) | 100.0% (14) |
Abbreviations: LAAO, left atrial appendage occlusion; SBP, systolic blood pressure; DBP, diastolic blood pressure; AF, atrial fibrillation; CHF, congestive heart failure; TIA, transient ischemic attack; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, Calcium channel blockers; NYHA; New York Heart Association.